Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OP-3136 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Part 1A Dose Escalation monotherapy | EXPERIMENTAL | - |
| Part 1B Dose Escalation in combination with fulvestrant | EXPERIMENTAL | - |
| Part 1C Dose Escalation in combination with palazestrant | EXPERIMENTAL | - |
| Part 2A Dose Expansion monotherapy - mBC | EXPERIMENTAL | - |
| Part 2A Dose Expansion monotherapy - mCRPC | EXPERIMENTAL | - |
| Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 1 | EXPERIMENTAL | - |
| Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| OP-3136 | DRUG | Selective inhibitor of HAT enzymes KAT6A and KAT6B |
| Fulvestrant | DRUG | Selective estrogen receptor degrader (SERD) |
| Palazestrant | DRUG | Complete estrogen receptor antagonist (CERAN) |
Key Inclusion Criteria: * Participants with advanced or metastatic ER+HER2- breast cancer, mCRPC, or NSCLC (Part 1) or advanced or metastatic ER+HER2- BC or mCRPC (Part 2). * Part 1A (Dose escalation for OP-3136 monotherapy): Participants must have a tumor that is unresectable or metastatic and for...
Top 20 of 84 competitors
OP-3136 is an investigational small molecule developed by Olema Oncology for advanced or metastatic ER+ HER2- breast cancer. It is also being studied in advanced or metastatic non-small cell lung cancer and castration-resistant prostate cancer. It is in Phase 1 clinical development and has not been approved by the FDA.
OP-3136 targets KAT6, a lysine acetyltransferase enzyme. By acting on this target, OP-3136 is designed as a small molecule therapeutic being evaluated in biomarker-selected patients with advanced or metastatic solid tumors, including ER+ HER2- breast cancer.
OP-3136 is being developed by Olema Oncology, Inc., which trades on Nasdaq under the ticker OLMA. The company is running the Phase 1 program for the asset in advanced or metastatic solid tumors, including ER+ HER2- breast cancer.
OP-3136 is in Phase 1 clinical development. It is investigational and is being studied in a single recruiting Phase 1 trial in advanced or metastatic solid tumors, including ER+ HER2- breast cancer, NSCLC, and mCRPC.
OP-3136 is being studied in the Phase 1 trial NCT06784193, titled Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors. The trial is recruiting, is controlled and randomized, and plans to enroll 180 participants across the United States, Australia, France, Hong Kong, Ireland, and Spain.
OP-3136 is being evaluated for advanced or metastatic ER+ HER2- breast cancer. The Phase 1 trial NCT06784193 also enrolls patients with metastatic breast cancer and lists fulvestrant and palazestrant among its conditions, and it is a biomarker-selected study in adults 18 years and older.